Radotinib

Radotinib

Radotinib (pronounced ra-DOH-ti-nib) is a type of tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). It is a second-generation drug that specifically targets the BCR-ABL fusion protein, a characteristic feature of CML.

Etymology

The name "Radotinib" is derived from the pharmaceutical company that developed it, Ilyang Pharmaceutical Co., Ltd., based in Seoul, South Korea. The "tinib" suffix is common among tyrosine kinase inhibitors.

Usage

Radotinib is used in the treatment of chronic phase and accelerated phase chronic myeloid leukemia (CML) in patients who are resistant to or intolerant of at least one prior therapy, including imatinib. It is administered orally.

Mechanism of Action

Radotinib inhibits the activity of BCR-ABL tyrosine kinase, an abnormal enzyme produced by the cells of patients with CML. By blocking this enzyme, radotinib prevents the growth of cancer cells and induces their death.

Side Effects

Common side effects of radotinib include anemia, neutropenia, thrombocytopenia, nausea, vomiting, and diarrhea. Serious side effects may include cardiac failure, hepatotoxicity, and hemorrhage.

Related Terms

• Tyrosine kinase inhibitor
• Chronic myeloid leukemia
• BCR-ABL
• Imatinib
• Anemia
• Neutropenia
• Thrombocytopenia
• Nausea
• Vomiting
• Diarrhea
• Cardiac failure
• Hepatotoxicity
• Hemorrhage

External links

• Medical encyclopedia article on Radotinib
• Wikipedia's article - Radotinib

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski